Table 2.
In vitro effects of methotrexate, etanercept, adalinumab, certolizumab, tocilizumab and hydroxychloroquine on K2P5.1 expression levels
| Substance | Concentration (μm) | CD4 T cells, unstimulated | CD4 T cells, stimulated |
|---|---|---|---|
| control | -- | 1.00 | 1.00 |
| methotrexate | 20 μM | 1.08 ± 0.18 | 0.93 ± 0.08 |
| etanercept | 10 μg/ml | 0.97 ± 0.07 | 1.01 ± 0.04 |
| adalinumab | 10 μg/ml | 0.96 ± 0.14 | 1.12 ± 0.05 |
| certolizumab | 10 μg/ml | 0.99 ± 0.09 | 1.14 ± 0.08 |
| tocilizumab | 10 μg/ml | 1.12 ± 0.22 | 1.24 ± 0.15 |
| hydroxychloroquine | 2 μg/ml | 0.82 ± 0.3 | 0.84 ± 0.35 |
Normalized values of K2P5.1 expression are depicted as mean ± SE.